

IN THE CLAIMS

1-17. (Canceled)

18. (New) A method for inhibiting angiogenesis comprising the steps of:

contacting a vertebrate animal predetermined to have a pathogenic angiogenesis with a metalloprotease inhibitor to specifically inhibit the activity of Kuz in the animal; and  
detecting a resultant inhibition of angiogenesis in the animal.

19. (New) A method according to claim 18, wherein the metalloprotease inhibitor is a TACE (TNF-alpha converting enzyme) inhibitor.

20. (New) A method according to claim 18, wherein the metalloprotease inhibitor is IC-3 (N-{D,L-[2-(hydroxyaminocarbonyl)methyl]-4-methyl-pentanoyl}-L-alanine, 2-aminoethyl amide).

21. (New) A method according to claim 18, wherein the metalloprotease inhibitor is GM6001 (NHOHCOCH<sub>2</sub>CH(I-Bu)CO-Trp-NHMe).

22. (New) A method according to claim 18, wherein the metalloprotease inhibitor is GW9471.

23. (New) A method according to claim 18, wherein the metalloprotease inhibitor is BB-94 (batimastat).

24. (New) A method according to claim 18, wherein the metalloprotease inhibitor is tissue inhibitor of metalloproteinase 1 (TIMP-1).

25. (New) A method according to claim 18, wherein the metalloprotease inhibitor is tissue inhibitor of metalloproteinase 1 (TIMP-2).

26. (New) A method according to claim 18, wherein the metalloprotease inhibitor is tissue

inhibitor of metalloproteinase 1 (TIMP-3).

27. (New) A method according to claim 18, wherein the metalloprotease inhibitor is a high-affinity zinc binding substituted hydroxamate.

28. (New) A method according to claim 18, wherein the metalloprotease inhibitor is a high-affinity zinc binding carboxylate.

29. (New) A method according to claim 18, wherein the metalloprotease inhibitor is a high-affinity zinc binding thiol.

30. (New) A method according to claim 18, wherein the metalloprotease inhibitor is a high-affinity zinc binding phosphonate.

31. (New) A method according to claim 18, wherein the metalloprotease inhibitor is a high-affinity zinc binding aminodithiazol.

32. (New) A method according to claim 18, wherein the metalloprotease inhibitor is a high-affinity zinc binding catechol.

33. (New) A method according to claim 18, wherein the metalloprotease inhibitor is EDTA.

34. (New) A method according to claim 18, wherein the metalloprotease inhibitor is 1,10-phenanthroline.